Role of plasmapheresis in the management of myeloma kidney: A systematic review

Hemodialysis International

Volumn 14, Issue 4, 2010, Pages 355-363

  Gupta, Diptesh ^a   Bachegowda, Lohith ^b   Phadke, Gautam ^a,c   Boren, Sue ^d,e   Johnson, Diane ^f   Misra, Madhukar ^a,c  

^a University of Missouri   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Division of Nephrology   (United States)

^d Department of Health Management and Informatics ^*  (United States)

^e University School of Medicine   (United States)

^f UNIVERSITY OF MISSOURI   (United States)

Author keywords

Acute renal failure; Multiple myeloma; Plasmapheresis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONVALESCENCE; DIALYSIS; DISEASE MANAGEMENT; HUMAN; KIDNEY FUNCTION; MULTIPLE MYELOMA; PLASMAPHERESIS;

ACUTE KIDNEY INJURY; HUMANS; MULTIPLE MYELOMA; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77958533137     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00481.x     Document Type: Article

References (41)

1. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am. 1992; 6:225-247.
2. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100:1672-1694.
3. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78:21-33.
4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994; 53:207-212.
5. Bladé J, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158:1889-1893.
6. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990; 150:1693-1695.
7. Pozzi C, Pasquali S, Donini U, et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: A review of 50 cases. Report of the Italian Renal Immunopathology Group. Clin Nephrol. 1987; 28:1-9.
8. Defronzo RA, Humphrey RL, Wright JR, Cooke CR. Acute renal failure in multiple myeloma. Medicine (Baltimore). 1975; 54:209-223.
9. Feest TG, Burge PS, Cohen SL. Successful treatment of myeloma kidney by diuresis and plasmaphoresis. Br Med J. 1976; 1:503-504.
10. Clark WF, Stewart AK, Rock GA, et al. Canadian Apheresis Group: Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143:777-784.
11. Cagnoli L, Pasquali S, Rovinetti C, Zucchelli P. Plasma exchange therapy in acute renal failure due to multiple myeloma. Life Support Syst. 1983; 1 (Suppl 1):102-105.
12. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990; 150:863-869.
13. Misiani R, Remuzzi G, Bertani T, et al. Plasmapheresis in the treatment of acute renal failure in multiple myeloma. Am J Med. 1979; 66:684-688.
14. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988; 33:1175-1180.
15. Moist L, Nesrallah G, Kortas C, Espirtu E, Ostbye T, Clark WF. Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol. 1999; 19:45-50.
16. Wahlin A, Lofvenberg E, Holm J. Improved survival in multiple myeloma with renal failure. Acta Med Scand. 1987; 221:205-209.
17. Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008; 73:1282-1288.
18. Kyle RA. Five decades of therapy for multiple myeloma: A paradigm for therapeutic models. Leukemia. 2005; 19:910-912.
19. Kyle RA. Henry Bence Jones-physician, chemist, scientist and biographer: A man for all seasons. Br J Haematol. 2001; 115:13-18.
20. Kyle RA. Multiple myeloma: How did it begin? Mayo Clin Proc. 1994; 69:680-683.
21. Bence JH. On the new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Lond Biol Sci. 1848; 138:55-62.
22. Clamp JR. Some aspects of the first recorded case of multiple myeloma. Lancet. 1967; ii:1354-1356.
23. Herrera GA. The kidney in plasma cell dyscrasias: A current view and a look at the future. Contrib Nephrol. 2007; 153:1-4.
24. Cohen DJ, Sherman WH, Osserman EF, Appel GB. Acute renal failure in patients with multiple myeloma. Am J Med. 1984; 76:247-256.
25. Montseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998; 13:1438-1445.
26. Ivanyi B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med. 1990; 114:986-987.
27. Isaac J, Herrera GA. Cast nephropathy in a case of Waldenstrom's macroglobulinemia. Nephron. 2002; 91:512-515.
28. Huang ZQ, Sanders PW. Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest. 1995; 73:810-817.
29. Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest. 1997; 99:732-736.
30. Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: The disease spectrum. J Am Soc Nephrol. 2001; 12:1482-1492.
31. Sanders PW, Booker BB. Altered loop segment function is the initial event in precipitation of low-molecular-weight proteins in the rat nephron. Contrib Nephrol. 1990; 83:100-103.
32. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest. 1992; 89:630-639.
33. Sanders PW, Booker BB, Bishop JB, Cheung HC. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest. 1990; 85:570-576.
34. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001; 158:1859-1866.
35. Batuman V, Guan S. Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am J Physiol. 1997; 272:F521-F530.
36. Batuman V, Verroust PJ, Navar GL, et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol. 1998; 275:F246-F254.
37. Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int. 2002; 62:1977-1988.
38. Clark WF. Correction: Plasma exchange when myeloma presents as acute renal failure. Ann Intern Med. 2007; 146:471.
39. Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a veterans affairs population. Ann Clin Lab Sci. 2006; 36:157-162.
40. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. J Am Soc Nephrol. 2007; 18:886-895.
41. Dexamethasone and Chemotherapy with or without Plasma Exchange in Patients with Newly Diagnosed Multiple Myeloma and Acute Kidney Failure. Available from (accessed December 6, 2010).